Cleared Traditional

K772002 - PLATES FOR HUMAN C4 COMPLEMENT

K772002 is an FDA 510(k) clearance for PLATES FOR HUMAN C4 COMPLEMENT, manufactured by G.D. Searle and Co.. The device is a Class 2 Immunology device with product code DBI cleared through the Traditional 510(k) pathway after a 12-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1977
Decision
12d
Days
Class 2
Risk

K772002 is an FDA 510(k) clearance for the PLATES FOR HUMAN C4 COMPLEMENT. Classified as Complement C4, Antigen, Antiserum, Control (product code DBI), Class II - Special Controls.

Submitted by G.D. Searle and Co. (Mchenry, US). The FDA issued a Cleared decision on November 2, 1977 after a review of 12 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5240 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all G.D. Searle and Co. devices

FDA 510(k) Submission Details - K772002

510(k) Number K772002 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 21, 1977
Decision Date November 02, 1977
Days to Decision 12 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
92d faster than avg
Panel avg: 104d · This submission: 12d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DBI Device Classification - Class 2, Special Controls

Product Code DBI Complement C4, Antigen, Antiserum, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5240
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.